Live Earnings Conference Call: Amicus Therapeutics will host a live Q1 2025 earnings call on May 1, 2025 at 8:30AM ET. Follow this link to get details and listen to Amicus Therapeutics' Q1 2025 earnings call when it goes live. Get details. Amicus Therapeutics (FOLD) Competitors $7.68 +0.16 (+2.13%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FOLD vs. EXAS, RGEN, HALO, MDGL, IONS, ALKS, LGND, BCRX, MNKD, and DVAXShould you be buying Amicus Therapeutics stock or one of its competitors? The main competitors of Amicus Therapeutics include Exact Sciences (EXAS), Repligen (RGEN), Halozyme Therapeutics (HALO), Madrigal Pharmaceuticals (MDGL), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Ligand Pharmaceuticals (LGND), BioCryst Pharmaceuticals (BCRX), MannKind (MNKD), and Dynavax Technologies (DVAX). These companies are all part of the "biotechnology" industry. Amicus Therapeutics vs. Exact Sciences Repligen Halozyme Therapeutics Madrigal Pharmaceuticals Ionis Pharmaceuticals Alkermes Ligand Pharmaceuticals BioCryst Pharmaceuticals MannKind Dynavax Technologies Exact Sciences (NASDAQ:EXAS) and Amicus Therapeutics (NASDAQ:FOLD) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation, dividends and community ranking. Which has better earnings and valuation, EXAS or FOLD? Amicus Therapeutics has lower revenue, but higher earnings than Exact Sciences. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Exact Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExact Sciences$2.76B3.07-$204.15M-$5.57-8.19Amicus Therapeutics$528.30M4.47-$151.58M-$0.18-42.67 Which has more volatility & risk, EXAS or FOLD? Exact Sciences has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Is EXAS or FOLD more profitable? Amicus Therapeutics has a net margin of -10.62% compared to Exact Sciences' net margin of -37.29%. Amicus Therapeutics' return on equity of 12.44% beat Exact Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Exact Sciences-37.29% -5.29% -2.45% Amicus Therapeutics -10.62%12.44%2.60% Do analysts recommend EXAS or FOLD? Exact Sciences currently has a consensus target price of $69.25, indicating a potential upside of 51.73%. Amicus Therapeutics has a consensus target price of $16.75, indicating a potential upside of 118.10%. Given Amicus Therapeutics' higher probable upside, analysts plainly believe Amicus Therapeutics is more favorable than Exact Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exact Sciences 0 Sell rating(s) 2 Hold rating(s) 19 Buy rating(s) 1 Strong Buy rating(s) 2.95Amicus Therapeutics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78 Does the MarketBeat Community believe in EXAS or FOLD? Exact Sciences received 459 more outperform votes than Amicus Therapeutics when rated by MarketBeat users. Likewise, 73.14% of users gave Exact Sciences an outperform vote while only 72.98% of users gave Amicus Therapeutics an outperform vote. CompanyUnderperformOutperformExact SciencesOutperform Votes99173.14% Underperform Votes36426.86% Amicus TherapeuticsOutperform Votes53272.98% Underperform Votes19727.02% Does the media refer more to EXAS or FOLD? In the previous week, Exact Sciences had 13 more articles in the media than Amicus Therapeutics. MarketBeat recorded 21 mentions for Exact Sciences and 8 mentions for Amicus Therapeutics. Amicus Therapeutics' average media sentiment score of 1.15 beat Exact Sciences' score of 0.91 indicating that Amicus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exact Sciences 12 Very Positive mention(s) 5 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amicus Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals believe in EXAS or FOLD? 88.8% of Exact Sciences shares are owned by institutional investors. 1.4% of Exact Sciences shares are owned by insiders. Comparatively, 2.2% of Amicus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryExact Sciences beats Amicus Therapeutics on 10 of the 19 factors compared between the two stocks. Get Amicus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FOLD vs. The Competition Export to ExcelMetricAmicus TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.36B$6.89B$5.57B$7.83BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-42.677.4422.4418.48Price / Sales4.47242.70394.09103.59Price / CashN/A65.8538.1834.62Price / Book12.196.516.774.25Net Income-$151.58M$143.21M$3.22B$248.23M7 Day Performance6.67%1.98%1.49%0.89%1 Month Performance-3.40%6.89%4.00%3.53%1 Year Performance-26.37%-2.52%16.21%5.08% Amicus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FOLDAmicus Therapeutics4.3773 of 5 stars$7.68+2.1%$16.75+118.1%-23.1%$2.36B$528.30M-42.67480News CoveragePositive NewsEXASExact Sciences4.3999 of 5 stars$43.10+3.7%$69.25+60.7%-23.1%$8.01B$2.76B-7.746,400Positive NewsRGENRepligen4.8903 of 5 stars$131.64+1.3%$176.82+34.3%-16.0%$7.39B$634.44M-258.122,020Earnings ReportAnalyst UpgradeNews CoverageHALOHalozyme Therapeutics4.0044 of 5 stars$57.29-2.6%$62.89+9.8%+61.2%$7.08B$1.02B16.70390Upcoming EarningsInsider TradeAnalyst RevisionMDGLMadrigal Pharmaceuticals3.7505 of 5 stars$295.02-2.2%$378.44+28.3%+63.7%$6.51B$180.13M-11.7690News CoveragePositive NewsGap DownIONSIonis Pharmaceuticals4.1826 of 5 stars$28.51+0.4%$56.72+99.0%-25.6%$4.53B$705.14M-9.38800Earnings ReportAnalyst ForecastNews CoverageALKSAlkermes4.618 of 5 stars$27.00flat$38.50+42.6%+17.2%$4.45B$1.56B12.442,280Analyst ForecastNews CoveragePositive NewsLGNDLigand Pharmaceuticals4.3943 of 5 stars$104.81-0.2%$146.43+39.7%+57.2%$2.02B$167.13M41.7680Upcoming EarningsNews CoverageBCRXBioCryst Pharmaceuticals4.4622 of 5 stars$7.53+1.8%$15.57+106.8%+114.3%$1.57B$450.71M-12.34530Upcoming EarningsAnalyst ForecastNews CoverageMNKDMannKind3.1277 of 5 stars$4.44-2.2%$9.56+115.4%+22.6%$1.35B$285.50M63.43400Upcoming EarningsPositive NewsDVAXDynavax Technologies4.1906 of 5 stars$10.44+1.3%$20.50+96.4%+3.3%$1.30B$277.25M58.00350Upcoming Earnings Related Companies and Tools Related Companies EXAS Alternatives RGEN Alternatives HALO Alternatives MDGL Alternatives IONS Alternatives ALKS Alternatives LGND Alternatives BCRX Alternatives MNKD Alternatives DVAX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FOLD) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amicus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amicus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy FOLD Stock Free FOLD Stock Alerts